Article
Immunology
Hao Qu, Yuankang Zhang, Rongxin He, Nong Lin, Cong Wang
Summary: Postmenopausal osteoporosis is a chronic systemic metabolic disease caused by excessive bone resorption and reduced bone formation. Anethole, a natural compound, shows potential in inhibiting osteoclast differentiation, reducing bone resorption, and suppressing osteoclast-specific gene expression through blocking ERK and AKT signaling pathways. Our study suggests that anethole may have osteoprotective effects and be a potential treatment for osteoporosis.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Yansi Xian, Yuangang Su, Jiamin Liang, Feng Long, Xiaoliang Feng, Yu Xiao, Haoyu Lian, Jiake Xu, Jinmin Zhao, Qian Liu, Fangming Song
Summary: Oroxylin A (OA), a natural flavonoid extracted from the root of Scutellaria baicalensis Georgi, demonstrates inhibitory effects on osteoclast formation and function induced by RANKL through regulating ROS and NFATc1. It exhibits protective effects against bone loss in animal models and in vitro experiments.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Immunology
Rong Hu, Libo Chen, Xiaolong Chen, Zhong Xie, Chao Xia, Yong Chen
Summary: Aloperine has been shown to inhibit osteoclast activity and formation mediated by RANKL, indicating its potential as a new drug for the prevention and treatment of postmenopausal osteoporosis.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Gang Wang, Chao Ma, Kai Chen, Ziyi Wang, Heng Qiu, Delong Chen, Jianbo He, Cheng Zhang, Ding Guo, Boyong Lai, Shuangxiao Zhang, Linfeng Huang, Fan Yang, Jinbo Yuan, Leilei Chen, Wei He, Jiake Xu
Summary: This study demonstrates that cycloastragenol (CAG) inhibits the formation and function of osteoclasts by regulating intracellular signaling pathways. It has potential as an alternative treatment for osteoporosis.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Immunology
Cong Xu, Shu-Qing Jin, Chen Jin, Zi-Han Dai, Yu-Hao Wu, Gao-Lu He, Hai-Wei Ma, Chao-Yi Xu, Wen-Lai Fang
Summary: The study aimed to investigate the effect and mechanism of Cedrol (Ced) in estrogen-deficient osteoporosis. The results demonstrated that Ced mitigated RANKL-induced osteoclastogenesis by reducing ROS content and inhibiting NFATc1, NF-KB, and MAPK signaling pathways. Additionally, Ced-mediated anti-osteolytic property was observed in ovariectomized mice. Thus, this study revealed the anti-osteoporotic potential of Cedrol in Ginger and provided more pharmacological evidence for Ginger as a food or medicine for bone metabolic disease.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Yin Cheng, Haixia Liu, Jing Li, Yujie Ma, Changheng Song, Yuhan Wang, Pei Li, Yanjing Chen, Zhiguo Zhang
Summary: Monascin was found to inhibit osteoclastogenesis in RANKL-induced RAW264.7 cells by suppressing MAPKs signaling pathways.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
HaiShan Li, Wei Deng, QiuLi Qin, YueWei Lin, Teng Liu, GuoYe Mo, Yang Shao, YongChao Tang, Kai Yuan, LiangLiang Xu, YongXian Li, ShunCong Zhang
Summary: This study investigated the effect of ISO on osteoclast differentiation and activation, as well as its molecular mechanism. In vitro experiments showed that ISO inhibited osteoclast generation and affected multiple molecular pathways related to bone homeostasis. In vivo experiments demonstrated that ISO effectively reduced bone loss caused by ovariectomy. These findings suggest that ISO may have therapeutic potential for the treatment of osteoporosis.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Jianbo He, Kai Chen, Tiancheng Deng, Jiewei Xie, Kunjing Zhong, Jinbo Yuan, Ziyi Wang, Zhifeng Xiao, Ronghe Gu, Delong Chen, Xiaojuan Li, Dingkun Lin, Jiake Xu
Summary: RH shows significant anti-catabolic effects by inhibiting osteoclastogenesis and bone resorption, potentially through suppressing Nox1 expression, enhancing antioxidant enzyme activity, and inhibiting MAPKs, NF-kappa B, and intracellular Ca2+ oscillation pathways. These findings suggest RH could be a promising natural small molecule for treating osteoporosis by inhibiting excessive osteoclast activity.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Guoju Hong, Zhenqiu Chen, Xiaorui Han, Lin Zhou, Fengxiang Pang, Rishana Wu, Yingshan Shen, Xiaoming He, Zhinan Hong, Ziqi Li, Wei He, Qiushi Wei
Summary: The study revealed that Robinin could prevent bone resorption by inhibiting osteoclastogenesis mediated by RANKL, reducing ROS production, and regulating molecular signaling pathways, making it a potential drug for treating osteoporosis.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Article
Chemistry, Medicinal
Yifeng Shi, Lin Ye, Shiwei Shen, Tianchen Qian, Youjin Pan, Yuhan Jiang, Jinghao Lin, Chen Liu, Yaosen Wu, Xiangyang Wang, Jiake Xu, Haiming Jin
Summary: The study demonstrated that morin can inhibit osteoclast formation through various pathways and attenuate bone loss induced by ovariectomy. This suggests that morin may be a potential therapeutic agent for postmenopausal osteoporosis treatment.
PHYTOTHERAPY RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Jing Li, Jiamin Liang, Liwei Wu, Yang Xu, Chengxiang Xiao, Xue Yang, Ran Sun, Jinmin Zhao, Jiake Xu, Qian Liu, Bo Zhou
Summary: The study suggests that CYT387 has potential as a drug candidate for treating osteoclast-related bone diseases.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Plant Sciences
Fangting He, Shuhan Luo, Sijing Liu, Siqi Wan, Jingjing Li, Jiayi Chen, Haojiang Zuo, Xiaofang Pei
Summary: Zanthoxylum bungeanum Maxim seed oil (ZBSO) has shown potential as an anti-bone loss agent by inhibiting osteoclastogenesis through the suppression of the ERK/c-JUN/NFATc1 pathway and regulation of cell cycle arrest induced by RANKL.
JOURNAL OF ETHNOPHARMACOLOGY
(2022)
Article
Chemistry, Medicinal
Yu Xiao, Yansi Xian, Xinmei Hu, Zhongquan Qi
Summary: In this study, it was found that D-(-)-salicin (DSA) can inhibit the formation and function of osteoclasts in osteoporosis by suppressing ROS signaling, MAPK, and NF-kappa B cascades.
Article
Pharmacology & Pharmacy
Guoju Hong, Lin Zhou, Guanqiang Zheng, Xiaoxia Zheng, Zhenqiu Chen, Wei He, Qiushi Wei
Summary: Liquiritin (LIQ) has the ability to inhibit osteoclast formation and bone-resorbing activity induced by RANKL, and it exerts its effects by reducing ROS levels and suppressing the Ca2+/MAPK-NFATc1 signaling pathway.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Cell Biology
Lingbo Kong, Rui Ma, Yang Cao, Wanli Smith, Yuan Liu, Xiaobin Yang, Liang Yan
Summary: This study compared the osteoclastic differentiation of two different cell lineages, RAW264.7(TIB-71) and RAW264.7(CRL-2278), and found that RAW264.7(TIB-71) demonstrated higher efficacy in RANKL-stimulated differentiation, leading to the formation of mature osteoclasts. In contrast, RANKL-induced RAW264.7(CRL-2278) cells did not form mature osteoclasts despite various pre-treatment conditions.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2021)
Article
Chemistry, Medicinal
Taotao Ling, My Tran, Miguel A. Gonzalez, Lekh Nath Gautam, Michele Connelly, Rachael K. Wood, Iram Fatima, Gustavo Miranda-Carboni, Fatima Rivas
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2015)
Article
Neurosciences
Geetika Kharkwal, Karen Brami-Cherrier, Jose E. Lizardi-Ortiz, Alexandra B. Nelson, Maria Ramos, Daniel Del Barrio, David Sulzer, Anatol C. Kreitzer, Emiliana Borrelli
Article
Multidisciplinary Sciences
Geetika Kharkwal, Daniela Radl, Robert Lewis, Emiliana Borrelli
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2016)
Article
Multidisciplinary Sciences
Iram Fatima, Ikbale El-Ayachi, Ling Taotao, M. Angeles Lillo, Raya Krutilina, Tiffany N. Seagroves, Tomasz W. Radaszkiewicz, Miroslav Hutnan, Viterslav Bryja, Susan A. Krum, Fatima Rivas, Gustavo A. Miranda-Carboni
Article
Oncology
V. Chandra, I. Fatima, R. Saxena, M. K. Hussain, K. Hajela, P. Sankhwar, B. G. Roy, S. Chandna, A. Dwivedi
GYNECOLOGIC ONCOLOGY
(2013)
Article
Biochemistry & Molecular Biology
Murli Manohar, Iram Fatima, Ruchi Saxena, Vishal Chandra, Pushp L. Sankhwar, Anila Dwivedi
JOURNAL OF NUTRITIONAL BIOCHEMISTRY
(2013)
Article
Biochemistry & Molecular Biology
I. Fatima, R. Saxena, G. Kharkwal, M. K. Hussain, N. Yadav, K. Hajela, P. L. Sankhwar, A. Dwivedi
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2013)
Article
Biochemistry & Molecular Biology
Ruchi Saxena, Iram Fatima, Vishal Chandra, Chellakkan S. Blesson, Geetika Kharkwal, Mohammad K. Hussain, Kanchan Hajela, Bal G. Roy, Anila Dwivedi
Article
Cell Biology
V. Chandra, I. Fatima, M. Manohar, P. Popli, V. K. Sirohi, M. K. Hussain, K. Hajela, P. Sankhwar, A. Dwivedi
CELL DEATH & DISEASE
(2014)
Article
Chemistry, Multidisciplinary
M. Kamil Hussain, M. Imran Ansari, N. Yadav, Puneet K. Gupta, A. K. Gupta, R. Saxena, I. Fatima, M. Manohar, P. Kushwaha, V. Khedgikar, J. Gautam, Ruchir Kant, P. R. Maulik, R. Trivedi, A. Dwivedi, K. Ravi Kumar, A. K. Saxena, K. Hajela
Article
Oncology
Ikbale El Ayachi, Iram Fatima, Peter Wend, Jackelyn A. Alva-Ornelas, Stephanie Runke, William L. Kuenzinger, Julio Silva, Wendy Silva, Joseph K. Gray, Stephan Lehr, Hilaire C. Barch, Raisa I. Krutilina, Andrew C. White, Robert Cardiff, Lisa D. Yee, Lily Yang, Ruth M. O'Regan, William E. Lowry, Tiffany N. Seagroves, Victoria Seewaldt, Susan A. Krum, Gustavo A. Miranda-Carboni
Article
Oncology
Maria Angeles Lillo Osuna, Jesus Garcia-Lopez, Ikbale El Ayachi, Iram Fatima, Aysha B. Khalid, Jerusha Kumpati, Alexandria V. Slayden, Tiffany N. Seagroves, Gustavo A. Miranda-Carboni, Susan A. Krum
Article
Oncology
Iram Fatima, Ikbale El-Ayachi, Hilaire C. Playa, Jackelyn A. Alva-Ornelas, Aysha B. Khalid, William L. Kuenzinger, Peter Wend, Jackelyn C. Pence, Lauren Brakefield, Raisa Krutilina, Daniel L. Johnson, Ruth M. O'Regan, Victoria Seewaldt, Tiffany N. Seagroves, Susan A. Krum, Gustavo A. Miranda-Carboni
Review
Oncology
Iram Fatima, Amar B. Singh, Punita Dhawan
Meeting Abstract
Oncology
Iram Fatima, Ikbale El Ayachi, Chidi Zacheaus, Joseph Kerby Gray, Raya Krutilina, Tiffany N. Seagroves, Susan A. Krum, Gustavo A. Miranda-Carboni